



Advances in Lung Diseases of Neonatal Medicine

Guest Editor:

Dr. Fumihiko Namba

Department of Pediatrics,
Saitama Medical center, Saitama
Medical University, 1981 Kamoda,
Kawagoe, Saitama 350-8550,
Japan

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Dear Colleagues,

Infants sometimes suffer from several lung diseases during their neonatal life, such as transient tachypnea of the newborn (TTNB), respiratory distress syndrome (RDS), meconium aspiration syndrome (MAS), pneumonia, pneumothorax, congenital diaphragmatic hernia (CDH), and bronchopulmonary dysplasia (BPD). Despite significant advances in perinatal and neonatal medicines, physicians and researchers are still trying to improve neonatal mortality and morbidities, potentially affecting both short- and long-term pulmonary outcomes in adulthood, using new techniques including new methods of surfactant administration for RDS, fetal therapy for CDH, and cell therapies for BPD.

We invite investigators to contribute original research as well as review articles addressing recent advances in lung diseases of neonatal medicine and their effects on both short-term and long-term pulmonary outcomes in children, adolescents, and adults. At the same time, research regarding the understanding of molecular mechanisms based on pharmacological treatments is welcome.

Dr. Fumihiko Namba
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)